GlassScriptPhysician profile
Melissa Daluvoy
NPI 1760657860
$13,241.80
in general payments reported to CMS, 2019-2025
10 companies · $9,926 in 2025
The $9,926 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $33.24 · 2022: $83.58 · 2023: $17.97 · 2024: $2,968 · 2025: $9,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,488 · Travel and Lodging: $2,021 · Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,487.50 |
| Travel and Lodging | $2,021.11 |
| Food and Beverage | $1,402.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $9,538.86 | 2020-2025 | Epioxa, Travoprost Intraocular Implant - Idose, Photrexa |
| Kedrion Biopharma, INC. | $2,400.00 | 2024 | Albuked, Koate, Rhogam Ultra-Filtered Plus |
| Johnson & Johnson Surgical Vision, INC. | $347.85 | 2022-2024 | Tecnis Simplicity, Tecnis Iol |
| Biotissue Holdings INC. | $266.99 | 2024 | |
| Quidel Corporation | $213.52 | 2019 | |
| Alcon Research LLC | $211.33 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $134.57 | 2025 | Xdemvy |
| Alcon Vision LLC | $83.43 | 2025 | |
| Dompe US, INC. | $27.28 | 2025 | Oxervate |
| Tela Bio, INC. | $17.97 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Daluvoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.